> ## Content Index
> Fetch the complete content index at: https://www.foodconsumer.org/llms.txt
> Use this file to discover other available public pages before exploring further.

# Aspirin Cuts Hepatocellular Carcinoma Risk
- URL: https://www.foodconsumer.org/aspirin_hepatocellular_carcinoma_1202120451/
- Published: 2012-12-02T17:50:00.000Z
- Updated: 2026-09-22T16:09:36.000Z
- Description: Among 300,504 adults in the NIH-AARP cohort, aspirin users had a 41 percent lower risk of hepatocellular carcinoma and a 45 percent lower risk of death from chronic liver disease. Non-aspirin NSAIDs tracked with 26 percent fewer such deaths but no change in liver cancer risk.
- Author: Food Consumer
- Tags: Nutrition, #vivvo-import

BY David Liu, PHD

Sunday Dec 2, 2012 (foodconsumer.org) -- People with chronic liver disease who take aspirin may reduce risk of developing hepatocellular carcinoma (HCC) and the risk of death from chronic liver disease, according to a study in Journal of National Cancer Institute.

Chronic liver disease may be some kind of inflammatory disease and nonsteroidal anti-inflammatory drugs (NSAIDS) like aspirin are known to be able to reduce chronic inflammation, which can lead to cancer. Actually these drugs have been associated with reduced risk of many cancers.

V. V. Sahasrabuddhe at Division of Cancer Epidemiology and Genetics, National Cancer Institute in Rockville, MD and colleagues conducted the study and found people with chronic liver disease using aspirin regardless of how often it was used reduced their risk of hepatocellular carcinoma and death from chronic liver disease by nearly 50%.

For the study, researchers analysed data on 300504 men and women aged 50 to 71 years in the National Institute of Health-AARP Diet and Health Study cohort to examine whether self-reported use of aspirin and nonaspirin NSAID use were associated with registry-confirmed diagnoses of hepatocellular carcinoma (250 cases) and death from chronic liver disease (428 cases) excluding hepatocellular carcinoma.

Aspirin use was associated with significantly (41%) reduced risk of hepatocellular carcinoma and 45% reduced risk of death from chronic liver disease, compared with those who did not take aspirin.

Use of nonaspirin NSAIDs was associated with a 26% reduced risk of death from chronic liver disease, but was not associated with risk of developing hepatocellular carcinoma, compared with those who did not take nonaspirin NSAIDs.

The frequency of aspirin use did not seem to affect the association between aspirin use and the risk of hepatocellular carcinoma and death from chronic liver disease. But the reduction in risk of death from chronic liver disease was significant only in those nonaspirin NSAID users who took the medications monthly, compared to non-users.

The researchers concluded "Aspirin use was associated with reduced risk of developing HCC and of death due to CLD (chronic liver disease) whereas nonaspirin NSAID use was only associated with reduced risk of death due to CLD."

Hepatocellular carcinoma is a major type of liver cancer, which is often times deadly.